FUSION PROTEINS: APPLICATIONS AND CHALLENGES - Fusion Protein Technologies for Biopharmaceuticals: Applications and Challenges - page 21

96. SuH, JackM,McIntoshLM, PerdomoL, ChoyBSF, FinckBK,
et al. (2009) Clinical grade production and characterization
of a fusion protein comprised of the chemokine CCL2-ligand
genetically fused to a mutated and truncated form of the
Shiga A1 subunit. Protein Expr. Purif. 66(2), 149-157.
97. Mohlmann S, Bringmann P, Greven S, Harrenga A. (2011)
Site-specific modification of ED-B-targeting antibody using
intein-fusion technology. BMC Biotechnol. 11, 76.
98. Premsukh A, Lavoie JM, Cizeau J, Entwistle J, MacDonald GC.
(2011) Development of a GMP Phase III purification process
for VB4-845, an immunotoxin expressed in E. coli using high
cell density fermentation. Protein Expr. Purif. 78(1), 27-37.
99. Omasa T, Onitsuka M, Kim W-D. (2010) Cell engineering
and cultivation of Chinese hamster ovary (CHO) cells. Curr.
Pharm. Biotechnol. 11(3), 233-240.
100. Barnes LM, Dickson AJ. (2006) Mammalian cell factories for
efficient and stable protein expression. Curr. Opin. Biotech-
nol. 17(4), 381-386.
101. Matasci M, Hacker DL, Baldi L, Wurm FM. (2008) Recom-
binant therapeutic protein production in cultivated mamma-
lian cells: current status and future prospects. DDT 5(2-3),
e37-e42.
102. Lim Y, Wong NSC, Lee YY, Ku SCY, Wong DCF, Yap MGS.
(2010) Engineering mammalian cells in bioprocessing—
current achievements and future perspectives. Biotechnol.
Appl. Biochem. 55(4), 175-189.
103. Liu YY, Gordienko I, Mathias A, Ma S, Thompson J, Woo JH,
et al. (2000) Expression of an anti-CD3 single-chain immu-
notoxin with a truncated diphtheria toxin in a mutant CHO
cell line. Protein Expr. Purif. 19(2), 304-311.
104. Grillberger L, Kreil TR, Nasr S, Reiter M. (2009) Emerging
trends in plasma-free manufacturing of recombinant protein
therapeutics expressed in mammalian cells. Biotechnol. J.
4(2), 186-201.
105. Qian Y, Jing Y, Li ZJ. (2010) Glucocorticoid receptor-medi-
ated reduction of IgG-fusion protein aggregation in Chinese
hamster ovary cells. Biotechnol. Prog. 26(5), 1417-1423.
106. Boado RJ, Hui EK-W, Lu JZ, Pardridge WM. (2011) CHO
cell expression, long-term stability, and primate pharmaco-
kinetics and brain uptake of an IgG-paroxonase-1 fusion
protein. Biotechnol. Bioeng. 108(1), 186-196.
107. Kalyanpur M. (2002) Downstream processing in the bio-
technology industry. Mol. Biotechnol. 22(1), 87-98.
108. Balasundaram B, Harrison S, Bracewell DG. (2009) Advan-
ces in product release strategies and impact on bioprocess
design. Trends Biotechnol. 27(8), 477-485.
109. Baneyx F, Mujacic M. (2004) Recombinant protein folding
and misfolding in Escherichia coli. Nat. Biotechnol. 22(11),
1399-1408.
110. Fahnert B, Lilie H, Neubauer P. (2004) Inclusion bodies:
formation and utilisation. Adv. Biochem. Eng. Biotechnol. 89,
93-142.
111. Hassouneh W, Christensen T, Chilkoti A. (2010) Elastin-like
polypeptides as a purification tag for recombinant proteins.
Curr. Protoc. Protein Sci. Chapter 6, Unit 6.11.

112. Ghose S, Hubbard B, Cramer SM. (2007) Binding capacity
differences for antibodies and Fc-fusion proteins on protein A
chromatographic materials. Biotechnol. Bioeng. 96(4), 768-779.
113. Xu X, Didio DM, Leister KJ, Ghose S. (2010) Disaggregation
of high-molecular weight species during downstream proc-
essing to recover functional monomer. Biotechnol. Prog.
26(3), 717-726.
114. Roque ACA, Lowe CR, Taipa MA. (2004) Antibodies and
genetically engineered related molecules: production and
purification. Biotechnol. Prog. 20(3), 639-654.
115. Nilson BH, Solomon A, Bjorck L, Akerstrom B. (1992)
Protein L from Peptostreptococcus magnus binds to the
kappa light chain variable domain. J. Biol. Chem. 267(4),
2234-2239.
116. Pigeon C, Jackson M, Baines D. (2009) Application of
Fabsorbent TM F1P HF, a synthetic ligand adsorbent for capture
and purification of a single-domain antibody fragment
expressed in Escherichia coli. Bio. Proc. Intl. 7(7), 90-91.
117. El Khoury G, Rowe LA, Lowe CR. (2012) Biomimetic
affinity ligands for immunoglobulins based on the multi-
component Ugi reaction. Methods Mol. Biol. 800, 57-74.
118. Willems A, Leoen J, Schoonooghe S, Grooten J, Mertens N.
(2003) Optimizing expression and purification from cell
culture medium of trispecific recombinant antibody deriva-
tives. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.
786(1-2), 161-176.
119. Lobbezoo B, Dodd R, Morton P, Duell M. (2011) A novel
high performance adsorbent as a platform process for the
capture & purification of albumin-fusion proteins. PREP
2011—24th International Symposium, 1.
120. (2002) Amediplase: CGP 42935, K2tu-PA, MEN 9036. Bio-
Drugs 16(5), 378-379.
121. Rosa PAJ, Azevedo AM, Sommerfeld S, Backer W, Aires-
BarrosMR. (2011) Aqueous two-phase extraction as a platform
in the biomanufacturing industry: economical and environ-
mental sustainability. Biotechnol. Adv. 29(6), 559-567.
122. Jorgensen L, Hostrup S, Moeller EH, Grohganz H. (2009)
Recent trends in stabilising peptides and proteins in pharma-
ceutical formulation—considerations in the choice of exci-
pients. Expert Opin. Drug Deliv. 6(11), 1219-1230.
123. Patro SY, Freund E, Chang BS. (2002) Protein formulation
and fill-finish operations. Biotechnol Annu. Rev. 8, 55-84.
124. Frokjaer S, Otzen DE. (2005) Protein drug stability: a for-
mulation challenge. Nat. Rev. Drug Discov. 4(4), 298-306.
125. Roberts CJ, Das TK, Sahin E. (2011) Predicting solution
aggregation rates for therapeutic proteins: approaches and
challenges. Int. J. Pharm. 418(2), 318-333.
126. Rathore N, Rajan RS. (2008) Current perspectives on stability
of protein drug products during formulation, fill and finish
operations. Biotechnol. Prog. 24(3), 504-514.
127. Haselbeck A. (2003) Epoetins: differences and their relevance
to immunogenicity. Curr. Med. Res. Opin. 19(5), 430-432.
128. Sharma B. (2007) Immunogenicity of therapeutic proteins.
Part 2: impact of container closures. Biotechnol. Adv. 25(3),
318-324.